跳到主要內容

臺灣博碩士論文加值系統

(3.236.84.188) 您好!臺灣時間:2021/08/02 19:51
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:陳鈺翰
研究生(外文):Yu-Han chen
論文名稱:大腸癌及鼻咽癌體外檢驗試劑套組之研發
論文名稱(外文):Development of in vitro Diagnostic Kits for Colon Cancer and Nasopharyngeal Carcinoma with Specific Panel of Antibodies
指導教授:詹爾昌
學位類別:碩士
校院名稱:長庚大學
系所名稱:醫學生物技術研究所
學門:醫藥衛生學門
學類:醫學技術及檢驗學類
論文種類:學術論文
論文出版年:2005
畢業學年度:93
語文別:中文
中文關鍵詞:大腸癌腫瘤相關抗原檢驗試劑
外文關鍵詞:colon cancertumor-associated antigens
相關次數:
  • 被引用被引用:0
  • 點閱點閱:137
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
在台灣,大腸癌的發生率高居十大癌症死亡原因第三位,但目前缺乏良好而快速的早期篩檢方法來使病人能早期接受治療。根據研究指出,部分腫瘤相關抗原能對自身抗體產生專一性反應。本研究使用9個大腸癌特異性腫瘤相關抗原,檢測病患血清中抗體反應。經檢測105個大腸癌病人及54個健康捐獻者,分別對大腸癌特異性抗原的血清反應,其中以編號N-CO-8、N-CO-9、N-CO-13、N-CO-16、N-CO-20五種抗原效果較好,靈敏度在17.1 %至36.8 %間。將結果聯集成多重抗原組合檢驗試劑,則病人對其中一種以上抗原有反應者的靈敏度為61.0 %,專一性為92.6 %。綜合CEA資料則靈敏度可提升為70.1 %,並且偵測到43.5 %的早期大腸癌病人。期望多重抗原組合的檢驗試劑套組,其快速而經濟的檢測方式,可大幅提高大腸癌病人的檢出率,並作為癌症的早期診斷。
Colon cancer has been listed as the third cause of death among cancers in Taiwan. However, the lack of an effective early detection screening methods is the major barrier to improve the treatment of patients with colon cancer. According to recent studies, some tumor-associated antigens can specifically recognize cancer patient’s autologous antibodies. Therefore, we used nine colon cancer antigens to detect specific antibodies in patient’s serum. Antibody reactivity against these antigens were determined in sera with from patients with colon cancer (n=105) and healthy donors (n=54). The five antigens which are named NY-CO-8, NY-CO-9, NY-CO-13, NY-CO-16 and NY-CO-20 got better reactivities, and sensitivity of these antigens was in the range of 17.1%- 36.8%. The combined analysis of the panel of the antibody reactivities, the sensitivity is 61.0 %, the specificity is 92.6 %. The addition analysis of CEA value could increase the sensitivity to 70.1% and, 43.5 % of the patients at early stages are detected. The ELISA format is cost-effective and feasible for mass screening; the specific panel of these profiles may be worth for early detection.
中文摘要………………………………………………………………….1
英文摘要………………………………………………….………………2
第一章 緒論…………………………………………………………….3
1.1 大腸癌簡介…………………………………………………...3
1.2 大腸癌分期及診斷…………………………………………...4
1.3 腫瘤相關抗原(tumor-associated antigens)……………….......7
第二章 研究目的…..………………………………………………….....9
第三章 材料…………….………………………………………………10
第四章 方法………………………………………………………….....14
第五章 結果………………………….………………...………………20
5.1 基因選殖與蛋白表現及純化…………………………….....20
5.2 基因選殖與蛋白表現及純化……………………………….23
5.3 重組蛋白的確認…………………………………………….24
第六章 討論………………..……………………….…………………..28
參考文獻………………………………………………………………...33
附圖……………………………………………………………………...38
附表……………………………………………………………………...51
附錄……………………………………………………………………...85
1.行政院衛生署衛生統計網(http://www.doh.gov.tw/statistic/)
2.曾永德(2003), 藝軒圖書出版社, 臨床鏡檢學.
3.Bergmann, U. and Beger, H.G. (2003) Endoscopic mucosal resection for advanced non-polypoid colorectal adenoma and early stage carcinoma. Surg Endosc, 17, 475-9.
4.Moertel, C.G., O'Fallon, J.R., Go, V.L., O'Connell, M.J. and Thynne, G.S. (1986) The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer, 58, 603-10.
5.Wang, W.S., Lin, J.K., Chiou, T.J., Liu, J.H., Fan, F.S., Yen, C.C., Lin, T.C., Jiang, J.K., Yang, S.H., Wang, H.S. and Chen, P.M. (2000) Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol, 30, 12-6.
6.林明泉主編(1997), 藝軒圖書出版社, 臨床血清免疫學, p685-687.
7.Lai, I.R., Lee, W.J., Huang, M.T. and Lin, H.H. (2002) Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterology, 49, 1157-60.
8.Wang, W.S., Lin, J.K., Chiou, T.J., Liu, J.H., Fan, F.S., Yen, C.C., Lin, T.C., Jiang, J.K., Yang, S.H., Wang, H.S. and Chen, P.M. (2002) CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology, 49, 160-4.
9.Knuth, A., Jager, D. and Jager, E. (2000) Cancer immunotherapy in clinical oncology. Cancer Chemother Pharmacol, 46 Suppl, S46-51.
10.Renner, C., Trumper, L. and Pfreundschuh, M. (2000) Tumour vaccines: a new immunotherapeutic approach in oncology. Ann Hematol, 79, 651-9.
11.Soussi, T. (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res, 60, 1777-88.
12.Koziol, J.A., Zhang, J.Y., Casiano, C.A., Peng, X.X., Shi, F.D., Feng, A.C., Chan, E.K. and Tan, E.M. (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res, 9, 5120-6.
13.Shawler, D.L., Bartholomew, R.M., Garrett, M.A., Trauger, R.J., Dorigo, O., Van Beveren, C., Marchese, A., Ferre, F., Duffy, C., Carlo, D.J., Sherman, L.A., Gold, D.P. and Sobol, R.E. (2002) Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin Exp Immunol, 129, 99-106.
14.Tureci, O., Sahin, U. and Pfreundschuh, M. (1997) Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today, 3, 342-9.
15.Cancer Immunome Database. ( http://www2.licr.org/CancerImmunomeDB/)
16.Scanlan, M.J., Chen, Y.T., Williamson, B., Gure, A.O., Stockert, E., Gordan, J.D., Tureci, O., Sahin, U., Pfreundschuh, M. and Old, L.J. (1998) Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer, 76, 652-8.

17.Zhang, J.Y., Casiano, C.A., Peng, X.X., Koziol, J.A., Chan, E.K. and Tan, E.M. (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev, 12, 136-43.
18.Line, A., Slucka, Z., Stengrevics, A., Silina, K., Li, G. and Rees, R.C. (2002) Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother, 51, 574-82.
19.Kenedy, A.A., Cohen, K.J., Loveys, D.A., Kato, G.J. and Dang, C.V. (2003) Identification and characterization of the novel centrosome-associated protein CCCAP. Gene, 303, 35-46.
20.Koesters, R., Linnebacher, M., Coy, J.F., Germann, A., Schwitalle, Y., Findeisen, P. and von Knebel Doeberitz, M. (2004) WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer, 109, 385-92.
21.CeMlines Inc. (http://www.cemines.com/)
22.Obata, Y., Takahashi, T., Sakamoto, J., Tamaki, H., Tominaga, S., Hamajima, N., Chen, Y.T. and Old, L.J. (2000) SEREX analysis of gastric cancer antigens. Cancer Chemother Pharmacol, 46 Suppl, S37-42.
23.Jager, D., Stockert, E., Gure, A.O., Scanlan, M.J., Karbach, J., Jager, E., Knuth, A., Old, L.J. and Chen, Y.T. (2001) Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res, 61, 2055-61.

24.Pavoni, E., Vaccaro, P., Pucci, A., Monteriu, G., Beghetto, E., Barca, S., Dupuis, M.L., De Pasquale Ceratti, A., Lugini, A., Cianfriglia, M., Cortesi, E., Felici, F. and Minenkova, O. (2004) Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage. BMC Cancer, 4, 78.
25.Pfreundschuh, M. (2000) Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother Pharmacol, 46 Suppl, S3-7.
26.Jager, E., Chen, Y.T., Drijfhout, J.W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L.J. and Knuth, A. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med, 187, 265-70.
27.Rohayem, J., Diestelkoetter, P., Weigle, B., Oehmichen, A., Schmitz, M., Mehlhorn, J., Conrad, K. and Rieber, E.P. (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 60, 1815-7.
28.Cai, X. and Garen, A. (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci U S A, 92, 6537-41.
29.Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I. and Pfreundschuh, M. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A, 92, 11810-3.
30.Stockert, E., Jager, E., Chen, Y.T., Scanlan, M.J., Gout, I., Karbach, J., Arand, M., Knuth, A. and Old, L.J. (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med, 187, 1349-54.
31.Park, J.W., Kwon, T.K., Kim, I.H., Sohn, S.S., Kim, Y.S., Kim, C.I., Bae, O.S., Lee, K.S., Lee, K.D., Lee, C.S., Chang, H.K., Choe, B.K., Ahn, S.Y. and Jeon, C.H. (2002) A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods, 266, 79-86.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top